To see all exchange delays and terms of use please see Barchart’s disclaimer. Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment. Yigal Nochomovitz’s rating for Ardelyx’s stock is based on a number of critical factors. He predicts a greater than 95% probability for the approval of Ardelyx’s drug, Xphozah, designed alvexo forex broker review for hyperphosphatemia patients on dialysis. This optimism stems from the positive Advisory Committee (AdCom) feedback last November and the Office of New Drugs’ (OND) unusual approval of Ardelyx’s appeal to the initial Complete Response Letter (CRL). Nochomovitz believes this indicates the drug’s approval is almost certain, with label negotiation being the only significant remaining hurdle.

The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. The Company’s product pipeline includes IBSRELA (tenapanor), XPHOZAH, RDX013 Program, and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C).

Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. 6 brokerages have issued twelve-month price targets for Ardelyx’s shares. Their ARDX share price forecasts range from $7.00 to $10.00. On average, they anticipate the company’s stock price to reach $8.25 in the next twelve months. This suggests a possible upside of 147.7% from the stock’s current price.

However, the 137% one-year return to shareholders may have helped lessen their pain. We would assume however, that they would be on the lookout for weakness in the future. According to 6 analysts, the average rating for ARDX stock is «Strong Buy.» The 12-month stock price forecast is $8.25, which is an increase of 147.75% from the latest price. It engages in the research, development, and commercialization of medicine for the treatment of cardiorenal diseases.

Upgrade to MarketBeat All Access to add more stocks to your watchlist. The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries.

How do I buy Ardelyx (ARDX) stock?

The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Waltham, MA. Ardelyx focuses on small molecules to treat diseases with significant unmet medical needs. The company’s only approved drug is Isbrela (tenapanor), approved to treat irritable bowel syndrome (IBS) with constipation. However, the company is coinberry review looking to add indications to tenapanor. A different version of the drug, called Xphozah, is looking to be approved to control serum phosphate levels in adults with CKD on dialysis or those who have had a poor response or intolerance to phosphate binder therapy. Xphozah has a Prescription Drug User Fee Act (PDUFA) date of Oct. 17 for Food and Drug Administration (FDA) approval.

  • Furthermore, the drug is expected to be beneficial for patients who don’t respond adequately or are intolerant to standard of care (SOC) phosphate binder therapy.
  • Nochomovitz covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Coherus Biosciences, and Atara Biotherapeutics.
  • Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits.
  • A different version of the drug, called Xphozah, is looking to be approved to control serum phosphate levels in adults with CKD on dialysis or those who have had a poor response or intolerance to phosphate binder therapy.
  • Ardelyx said a second Phase 3 study of tenapanor, a drug targeting irr…

Since 1988 it has more than doubled the S&P 500 with an average gain of +24.17% per year. These returns cover a period from January 1, 1988 through September 4, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.

The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. Plus, ARDX info will be updated daily in your Portfolio Tracker – also free.

Is Ardelyx (ARDX) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap

The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Ardelyx already has institutions on the share registry.

This implies the analysts working for those institutions have looked at the stock and they like it. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It’s therefore worth looking at Ardelyx’s earnings history below. Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development.

Does Ardelyx stock pay dividends?

Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. Ardelyx’s stock is owned by a number of institutional and retail investors. Top institutional shareholders include SG Americas Securities LLC (0.10%) and FNY Investment Advisers LLC (0.00%).

Novo’s news also hurt several kidney dialysis provider stocks as well. The company was founded in 2007 and is based in Fremont, California. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least.

Stock Money Flow

So they generally do consider buying larger companies that are included in the relevant benchmark index. TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Nochomovitz axitrader review covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Coherus Biosciences, and Atara Biotherapeutics. According to TipRanks, Nochomovitz has an average return of 4.1% and a 39.37% success rate on recommended stocks. Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank, Member FDIC.

XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

The company said it would launch the drug in the fourth quarter, pending approval. Ardelyx also has a pipeline candidate, RDX013, that is in phase 2 trials to lower potassium levels to treat CKD. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please see disclaimer.

About Ardelyx (NASDAQ:ARDX) Stock

The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Ardelyx Inc.’s investigational kidney disease drug tenapanor failed to meet the primary endpoint of a mid-stage clinical trial in patients with Stage 3 chronic kidney disease with Type 2 diabetes mellitus and albuminuria. Shares in Ardelyx Inc. plummeted more than 70% in after-hours trading Monday, following the biopharmaceutical company’s that the Food and Drug Administration appears unlikely to approve a drug for dialysis patients. The announcement by Novo Nordisk regarding Ozempic takes the wind out of potential Xphozah approval.